8.57
0.19 (2.27%)
| 前收盘价格 | 8.38 |
| 收盘价格 | 8.11 |
| 成交量 | 37,349 |
| 平均成交量 (3个月) | 71,668 |
| 市值 | 376,147,584 |
| 市盈率 (P/E TTM) | 171.40 |
| 价格/销量 (P/S) | 45.95 |
| 股市价格/股市净资产 (P/B) | 21.88 |
| 52周波幅 | |
| 利润日期 | 28 Apr 2025 |
| 营业毛利率 | 28.99% |
| 营业利益率 (TTM) | -68.64% |
| 稀释每股收益 (EPS TTM) | 0.050 |
| 季度收入增长率 (YOY) | -36.10% |
| 季度盈利增长率 (YOY) | 136.50% |
| 流动比率 (MRQ) | 10.71 |
| 营业现金流 (OCF TTM) | 2.08 M |
| 杠杆自由现金流 (LFCF TTM) | 1.27 M |
| 资产报酬率 (ROA TTM) | 7.18% |
| 股东权益报酬率 (ROE TTM) | 14.83% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Instruments & Supplies (US) | 看跌 | 混合的 |
| Medical Instruments & Supplies (全球的) | 看跌 | 看跌 | |
| 股票 | Anbio Biotechnology | - | - |
AIStockmoo 评分
| 分析师共识 | -2.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.75 |
|
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions. |
|
| 部门 | Healthcare |
| 行业 | Medical Instruments & Supplies |
| 投资方式 | Small Core |
| 内部持股比例 | 4.78% |
| 机构持股比例 | 4.94% |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 15 May 2025 | 公告 | Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合